ERC Starting Grant · 2018
Vessel co-option and radioresistance in glioblastoma
Glioblastoma (GBM) is one of the deadliest types of human cancer. Despite a very aggressive treatment regime – including resection of the tumor, radiation and chemotherapy – its estimated recurrence rate is more than 90%. Recurrence is mostly caused by the regrowth of highly invasive cells spreading from the tumor bulk, which are not removed by resection. To develop an effective therapeutic approach, we need to better understand the underlying molecular mechanism of radiation resistance and tumor spreading in GBM. Radioresistance in GBM is attributed to glioma stem cells (GSCs), a fraction of perivascular, self-renewing, multipotent and tumor-initiating cells. Growing evidence highlights…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.